Articles by Rich Whitworth - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Rich Whitworth

Jobs and Innovation

Nov 1, 2011

The middle word in our magazine's title is technology, so I cannot fail to join the increasing numbers of people in all fields of business commenting on the passing of Steve Jobs.

NPOs lead the way at CPhI

Oct 26, 2011

Another very busy day at CPhI Worldwide and co-located events with good meetings in every corner for all exhibitors.

Live at CPhI: Innovation Award Winners

Oct 26, 2011

PTE Editor, Rich Whitworth, gives an update on Day 1 of CPhI, including the Innovation Awards.

Live at CPhI: And so it begins!

Oct 24, 2011

PTE Editor, Rich Whitworth, reports on the CPhI pre-show conference.

Roche to Acquire Anadys Pharmaceuticals

Oct 20, 2011

Roche signed a definitive agreement to acquire Anadys Pharmaceuticals. The two companies have entered into a definitive merger agreement for Roche to fully acquire Anadys at a price of $3.70 per share in an all-cash transaction.

EMA Board Endorses 'Road Map to 2015'

Oct 13, 2011

After announcing the official appointment of Guido Rasi as new executive director, the EMA management board also endorsed the implementation plan for the agency's 'Road Map to 2015.'

EMA Invites Feedback on Biosimilar and Vaccine Concept Papers

Oct 6, 2011

EMA released two concept papers for consultation that address the need to revise existing guidelines on biosimilar medicines and influenza vaccines.

Taking It For Granted

Oct 1, 2011

As editor of Pharmaceutical Technology Europe, I often have the opportunity to visit the sites of a wide variety of companies within the industry. Though differing vastly in the technologies and staff they employ, they all share one thing in common for me: the "you learn something new every day!" factor.

Pfizer Plans Manufacturing Investment in Ireland; Alkermes Secures Supply Pact

Sep 22, 2011

Pfizer plans to invest EUR 145 million ($200 million) in its Grange Castle biotech-manufacturing site. Meanwhile, completion of the merger between Alkermes, Inc. and Elan Drug Technologies was announced in a press release on Sept. 16, 2011, following the approval by Alkermes, Inc. shareholders on Sept. 8, 2011.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
FindPharma Custom Search
Click here